2m 2m 2m 2m 2m 2m 2m
VERA THERAPEUT-A (VERA)
NASDAQ
$38.35-$0.08 (-0.21%)
Price as of Jun 23, 2026 6:54 PM EDT- $2.8BMarket Cap
- 77.51%1-Year Change
- BiotechnologyIndustry
VERA THERAPEUT-A (VERA)
$38.35-$0.08 (-0.21%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 393,000 +176.76% | 142,000 -70.11% | 475,000 +312.05% | -224,000 N/A | |
Cost of Revenue | 300,000 0.00% | 300,000 -89.29% | 2.8M N/A | N/A N/A | |
Gross Profit | 93,000 +158.86% | -158,000 -93.20% | -2.3M +937.95% | -224,000 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -215.3M +70.61% | -126.2M +61.29% | -78.2M +13.38% | -69.0M +206.85% | |
Depreciation and Amortization Expense | 468,000 +345.71% | 105,000 +102.57% | -4.1M +382.98% | -846,000 -580.68% | |
Total Operating Expenses | 315.5M +88.71% | 167.2M +63.87% | 102.0M +12.22% | 90.9M +164.24% | |
Operating Profit | -315.5M +88.71% | -167.2M +63.87% | -102.0M +12.22% | -90.9M +164.24% | |
Interest Income | 24.5M +18.18% | 20.7M +159.61% | 8.0M +355.94% | 1.8M +11,566.67% | |
Interest Expense | N/A N/A | N/A N/A | -3.8M +281.65% | -992,000 +4,860.00% | |
Interest Income and Expense and Net | 24.5M +18.18% | 20.7M +394.01% | 4.2M +453.17% | 758,000 +15,260.00% | |
Total Nonoperating Income and Expense | 15.9M +5.56% | 15.0M +149.43% | 6.0M +225.92% | 1.8M +3.01% | |
Income before Taxes | -299.6M +96.92% | -152.1M +58.50% | -96.0M +7.79% | -89.1M +173.11% | |
Income Taxes | 1,000 0.00% | 1,000 0.00% | 1,000 0.00% | 1,000 +200.00% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -299.6M +96.92% | -152.1M +58.50% | -96.0M +7.79% | -89.1M +173.10% | |
Net Income from Continuing Operations Applicable to Common | -299.6M +96.92% | -152.1M +58.50% | -96.0M +7.79% | -89.1M +173.11% | |
Basic EPS and Net Income | -4.66 +69.45% | -2.75 +22.22% | -2.25 -32.84% | -3.35 +37.86% | |
Diluted EPS and Net Income | -4.66 +69.45% | -2.75 +22.22% | -2.25 -32.84% | -3.35 +37.86% | |
Basic Weighted Average Shares | 64.2M +16.10% | 55.3M +29.55% | 42.7M +60.73% | 26.6M +97.76% | |
Diluted Weighted Average Shares | 64.2M +16.10% | 55.3M +29.55% | 42.7M +60.73% | 26.6M +97.76% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 354.7M +282.88% | 92.6M +102.81% | 45.7M +5.11% | 43.5M -45.45% | |
Short-Term Investments | 359.9M -34.36% | 548.2M +376.56% | 115.0M +61.58% | 71.2M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 714.6M +11.51% | 640.9M +298.75% | 160.7M +40.18% | 114.7M +43.90% | |
Total Current Assets | 728.9M +11.93% | 651.2M +278.56% | 172.0M +36.85% | 125.7M +52.29% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 1.4M +43.13% | 960,000 +943.48% | 92,000 +80.39% | 51,000 N/A | |
Total Long-Term Assets | 1.4M +43.13% | 960,000 +832.04% | 103,000 -5.50% | 109,000 -87.43% | |
Total Assets | 734.7M +12.06% | 655.7M +273.51% | 175.5M +33.56% | 131.4M +56.94% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 2.8M +172.02% | |
Total Current Liabilities | 53.5M +110.69% | 25.4M +13.76% | 22.3M -12.88% | 25.6M +232.90% | |
Total Long-Term Debt | 74.8M +47.65% | 50.7M +1.62% | 49.9M +101.04% | 24.8M +403.96% | |
Total Long-Term Liabilities | 76.8M +44.40% | 53.2M +3.67% | 51.3M +79.02% | 28.6M +481.78% | |
Total Liabilities | 130.2M +65.82% | 78.5M +6.32% | 73.9M +35.46% | 54.5M +285.19% | |
Retained Earnings | -760.9M +64.96% | -461.3M +49.22% | -309.1M +45.04% | -213.1M +71.79% | |
Total Stockholders Equity | 604.5M +4.74% | 577.2M +467.59% | 101.7M +32.22% | 76.9M +10.51% | |
Total Shares Outstanding | 71.3M +12.13% | 63.6M +42.98% | 44.5M +59.89% | 27.8M +30.66% | |
Cash Flow | |||||
Cash from Operating Activities | -241.1M +79.02% | -134.7M +46.10% | -92.2M +36.37% | -67.6M +185.12% | |
Capital Expenditures | 630,000 -35.19% | 972,000 +1,442.86% | 63,000 +1.61% | 62,000 -37.37% | |
Cash from Investing Activities | 194.3M +145.71% | -425.0M +977.91% | -39.4M -44.11% | -70.6M +1,578.21% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 308.9M -49.08% | 606.7M +354.30% | 133.5M +31.01% | 101.9M +89.18% | |
Financials Ratio | |||||
Gross Margin | 23.66% +121.27% | -111.27% -77.27% | -489.47% N/A | N/A N/A | |
Operating Margin | -80,273.03% -31.81% | -117,725.35% +448.17% | -21,476.21% -152.92% | 40,581.70% N/A | |
Return on Assets | -43.10% +17.73% | -36.61% -41.46% | -62.54% -24.45% | -82.77% N/A | |
Return on Equity | -50.71% +13.13% | -44.83% -58.30% | -107.50% -11.58% | -121.58% N/A | |
Revenue Growth | 176.76% +352.14% | -70.11% -122.47% | 312.05% N/A | N/A N/A | |
Current Ratio | 13.64 -46.88% | 25.67 +232.79% | 7.71 +57.08% | 4.91 N/A | |
Cash Ratio | 6.64 +81.73% | 3.65 +78.28% | 2.05 +20.65% | 1.70 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | 0.36 N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | 0.21 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow